One of the central ideas in management of advanced NSCLC is that many two-drug chemo combinations have been compared and show essentially superimposable results, as I described in a prior post.

I’m just coming from a meeting on Targeted Therapies in the Treatment of Lung Cancer, which had the interesting format of dozens of 5-minute presentations just introducing or giving a very brief update of many new therapies. Some of these, such as the EGFR monoclonal antibody Erbitux (cetixumab), which I spoke on, have been approved by the US FDA for several years in other cancer settings and are well tested in humans.